Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Eur J Clin Nutr. 2010 Dec;64(12):1415-22. doi: 10.1038/ejcn.2010.169. Epub 2010 Sep 8.
BACKGROUND/OBJECTIVES: Controversies surround the actual requirements of vitamin D in adolescents. We aimed to assess the efficacy and safety of different doses of vitamin D in high schoolchildren of Taleghan (latitude 36.5°N) near Tehran.
SUBJECTS/METHODS: In a randomized double-blind, placebo-controlled trial, 210 subjects, aged 14-20 years, 105 boys and 105 girls were assigned to three groups; group A (n=70) received 50 000 U oral cholecalciferol monthly (equal to 1600 U per day), group B (n=70), 50 000 U bimonthly (equal to 800 U/day) and group C (n=70), placebo. The study began in November 2007 and continued until April 2008. Serum 25(OH)D, parathyroid hormone (PTH), calcium (Ca) and bone markers were measured.
At baseline, girls had significantly lower concentrations of 25(OH)D than boys (19.25±16 vs 40.5±14 nmol/l). Mean 25(OH)D increased from 32±22 to 60±27.5 and 28.25±14.5 to 45.75±24 in groups A and B, respectively (P<0.001); however, it did not change over time in group C (29±18 vs 29±17.5). Increment of mean 25(OH)D was higher in group A than in group B (P<0.01). In all groups, girls had lower concentrations of 25(OH)D than boys (P<0.001). Serum Ca increased and PTH decreased in groups A and B (P<0.001). In group A, osteocalcin (OC) and bone-specific alkaline phosphatase increased (P<0.001), but in group B only OC increased (P<0.001). Urine C telopeptide and Ca did not change in all three groups; no case of hypercalcemia was observed.
Although monthly administration of 50 000 U vitamin D(3) increased serum 25(OH)D significantly, it was apparently not enough to correct vitamin D deficiency, especially in girls.
背景/目的:青少年维生素 D 的实际需求存在争议。我们旨在评估不同剂量维生素 D 在德黑兰附近大不里士(北纬 36.5°)高中生中的疗效和安全性。
受试者/方法:在一项随机、双盲、安慰剂对照试验中,将 14-20 岁的 210 名受试者(105 名男孩和 105 名女孩)分为三组;A 组(n=70)每月口服 50,000 IU 胆钙化醇(相当于每天 1600 IU),B 组(n=70)每两个月口服 50,000 IU(相当于每天 800 IU),C 组(n=70),安慰剂。研究于 2007 年 11 月开始,持续至 2008 年 4 月。测量血清 25(OH)D、甲状旁腺激素(PTH)、钙(Ca)和骨标志物。
基线时,女孩的 25(OH)D 浓度明显低于男孩(19.25±16 对 40.5±14 nmol/l)。A 组和 B 组的平均 25(OH)D 分别从 32±22 增加到 60±27.5 和 28.25±14.5 增加到 45.75±24(P<0.001);然而,C 组的 25(OH)D 浓度在整个时间内没有变化(29±18 对 29±17.5)。A 组的平均 25(OH)D 增加幅度高于 B 组(P<0.01)。在所有组中,女孩的 25(OH)D 浓度均低于男孩(P<0.001)。A 组和 B 组的血清 Ca 增加,PTH 降低(P<0.001)。在 A 组,骨钙素(OC)和骨特异性碱性磷酸酶增加(P<0.001),但在 B 组仅 OC 增加(P<0.001)。三组尿 C 端肽和 Ca 均无变化;未观察到高钙血症病例。
尽管每月给予 50,000 IU 维生素 D(3)可显著增加血清 25(OH)D,但显然不足以纠正维生素 D 缺乏症,尤其是在女孩中。